Tag archive for ‘Cryoport Second Quarter Results’
Cryoport: Reiterating My Buy Recommendation (CYRX, Buy, $14.20)
Investment Perspective On May 16, 2018, I published a report entitled Updated Sales and Earnings Model. The purpose of that report was to build a detailed sales model for the Company that for the first time incorporated Cryoport revenues arising from the sale of commercial products-the CAR-T drugs Kymriah and Yescarta. You may want to […]